Refine
Has Fulltext
- yes (29)
Is part of the Bibliography
- yes (29)
Year of publication
Document Type
- Journal article (29)
Language
- English (29)
Keywords
- CXCR4 (10)
- theranostics (8)
- PET (7)
- PRRT (4)
- adrenocortical carcinoma (4)
- chemokine receptor (4)
- molecular imaging (4)
- multiple myeloma (4)
- PET/CT (3)
- endoradiotherapy (3)
- prostate cancer (3)
- radioligand therapy (3)
- C-X-C motif chemokine receptor 4 (2)
- DOTATOC (2)
- NET (2)
- PSMA (2)
- SSTR (2)
- [68Ga]PentixaFor (2)
- fibroblast activation protein (2)
- medicine (2)
- radionuclide therapy (2)
- sarcoidosis (2)
- somatostatin receptor (2)
- 11C-Methionine PET/CT (1)
- 18F-FDG PET/CT (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- Arginine (1)
- COVID-19 (1)
- CTNNB1 (1)
- CXCR4-targeting (1)
- CXCR4/SDF-1 (1)
- CXCR7 (1)
- CYP11B enzymes (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- DOTA-EB-TATE (1)
- FDG (1)
- FDG PET/CT (1)
- Hyperkalaemia (1)
- IMAZA (1)
- Lysine (1)
- MAG3 (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- NR3C1 (1)
- PSMA I&T (1)
- PSMA-617 (1)
- Pentixafor (1)
- Positron emission tomography (1)
- Positronen-Emissions-Tomografie (1)
- SARS-CoV-2 (1)
- Somatostatin receptor expression (1)
- USP28 (1)
- USP8 (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- adrenal incidentaloma (1)
- agreement (1)
- amino acids (1)
- androgen deprivation therapy (1)
- autologous transplantation (1)
- biokinetics (1)
- biomarker (1)
- bone disease (1)
- buparlisib (1)
- c-MYC (1)
- cancer (1)
- cells (1)
- comparability (1)
- detection rate (1)
- evans blue (1)
- gefitinib (1)
- glucocorticoid excess (1)
- head and neck cancer (1)
- hypercortisolism (1)
- hyperkalemia (1)
- in vivo imaging (1)
- intraindividual comparison (1)
- involvement (1)
- kidney function (1)
- lung cancer (1)
- malignancies (1)
- matched pair (1)
- metabolic tumour volume (MTV) (1)
- microenvironment (1)
- neuroendocrine tumor (1)
- overall survival (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (1)
- pleural mesothelioma (1)
- positron emission tomography (1)
- prediction (1)
- prognosis (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- recurrence (1)
- recurrent prostate cancer (1)
- salvage radiotherapy (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin receptors (1)
- survival (1)
- total lesion PSMA (1)
- vemurafenib (1)
- vestibular schwannoma (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (29)
- Medizinische Klinik und Poliklinik I (8)
- Pathologisches Institut (8)
- Medizinische Klinik und Poliklinik II (7)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (5)
- Urologische Klinik und Poliklinik (5)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (1)
EU-Project number / Contract (GA) number
- 701983 (1)
Background
Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment.
Methods
To non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically proven MCC SSTR-PET was performed and compared to results of computed tomography (CT).
Results
SSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were up-staged due to SSTR-PET and patient management was changed in 3 patients (13%).
Conclusion
SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management.